Cannabis: From Pariah to Prescription
Learn more about tomorrow's alternative to today's risk-laden prescription drugs!
Cannabis: From Pariah to Prescription reviews the latest research from recent clinical trials with cannabis and cannabinoids—outlining their place and future as prescription medicines. This book addresses the “road back” for cannabis medicines and society's reacceptance of cannabis as a prescription product. This book offers physicians, patients, scientists, and students a primer on this developing branch of pharmacology and therapeutics and is ideal for use in courses for medicine, psychopharmacology, alternative medicine, health policy, and pharmacology.
Cannabis: From Pariah to Prescription assesses the genetics, horticulture, and biochemical processing of cannabis into cannabis-based medicine extracts (CBMEs). The book describes the important advanced technologies used to cultivate the genetically selected medical-grade cannabis cloned strains in glass houses. This book also discusses new advancements in drug delivery alternatives to traditional smoking, including the Advanced Delivery System (ADS)—a device that allows delivery of premeasured dosages while remaining secure, tamper-proof, and patient specific.
In Cannabis: From Pariah to Prescription, the practical applications of cannabis pharmaceuticals are explored through a wide range of clinical studies, including:
What people are saying - Write a review
We haven't found any reviews in the usual places.
Cannabis From Pariah to Prescription
GW Pharmaceuticals List of Abbreviations and Definitions of Terms
A Single Centre PlaceboControlled Four Period Crossover Tolerability Study Assessing Pharmacodynamic Effects Pharmacokinetic Characteristics an...
A Phase I Open Label FourWay Crossover Study to Compare the Pharmacokinetic Profiles of a Single Dose of 20 mg of a Cannabis Based Medicine ...
A Phase I Double Blind ThreeWay Crossover Study to Assess the Pharmacokinetic Profile of Cannabis Based Medicine Extract CBME Administered ...
11-hydroxy-THC 20 mg CBD 20 mg THC Adverse Events aerosol analysis Arithmetic mean assessment Based Medicine Extract blood pressure blood sample buccal cannabidiol cannabis and cannabinoids cannabis based medicine cannabis extracts Cannabis Therapeutics CBD and THC CBD:THC sublingual drops CBME concentrations of CBD concentrations of THC conjunctival reddening disorders drug endocannabinoid Ethan Russo FIGURE following administration formulation G. W. Guy Geometric mean Grinspoon GW Pharmaceuticals Haworth Haworth Press High CBD High THC hydroxy-THC inhaled intra-subject LLOQ maximum McPartland Mean concentrations medical marijuana Medicine Extract CBME minimum-maximum multiple sclerosis NC NC NC nebuliser ng/ml oral capsule pain Paraesthesia Pariah to Prescription patients period pharmacodynamic Pharmacokinetic PK parameters placebo plasma levels post-study pressurised aerosol randomised Robson screening single dose SL Drops spasticity spray subjects were required Table test treatment THC and 11-hydroxy-THC THC and CBD THC and CBD:THC THC:CBD Tmax Tourette syndrome Whittle